Trials BRAVE AA1 and BRAVE AA2 report Baricitinib to treat Alopecia Areata - Video

Published On 2022-04-04T17:00:52+05:30 | Updated On 4 April 2022 5:00 PM IST

Overview

Alopecia areatai.e hair loss is a known autoimmune condition affecting the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral selective is known to cure hair loss.

Nearly 40% of adults with alopecia areata taking baricitinib, an oral Janus kinase (JAK) 1 and 2 inhibitors, see significant hair regrowth over 52 weeks, according to updated results from two phases 3 trials presented at the American Academy of Dermatology 2022 annual meeting.

The results indicated improved response rates and hair growth among trial participants study findings are published in The New England Journal of Medicine. All patients enrolled in the two trials, called BRAVE-AA1 and BRAVE-AA2, had severe alopecia areata, defined as a Severity of Alopecia Tool (SALT) score of ≥ 50, meaning 50% or less scalp coverage.

Speakers

Dr. Nandita Mohan

BDS, MDS( Pedodontics and Preventive Dentistry)

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751